BARCELONA, Spain, July 27, 2020
BARCELONA, Spain, July 27, 2020 /PRNewswire/ --
Financial highlights (€ million)
YTD June 2020
YTD June 2019
- Net Sales
- Other Income
- % of sales
Normalized Net Income
 CER (Constant Exchange Rates): Excluding the effects of exchange rate fluctuations
The global COVID-19 pandemic continues to evolve, forcing Almirall to face an unprecedented and challenging scenario. The company has managed to respond to this situation in a manner that has limited its impact on operating results, maintaining stability in an otherwise unstable period. Since the beginning of the crisis, Almirall has focused its efforts on offering a strong response to the needs of the sector.
Peter Guenter, CEO: "The reduction in the number of patient visits due to lockdown and the change in prescription habits have had a negative impact on our results for the first half of the year. This fact, together with Aczone® facing generic competition, has caused a decrease in our Net Sales. We have adapted our commercial models in response to this new reality, allowing HCPs to keep in contact with our teams through virtual means."
"Our pipeline remains strong, following the execution of exciting deals, such as those announced in January with Bioniz and 23andMe, and the expected global launch of Tirbanibulin in early 2021, as well as the initiation of Phase III trials for Seysara in China later this year. These assets, together with Lebrikizumab, have the potential to deliver an exciting new era of growth for Almirall. Supported by this positive long-term outlook, we continue to focus on developing a portfolio of differentiated products, building the value of our pipeline, and prioritizing strategic opportunities to address patients' unmet needs".
Further information from Almirall's Q2 results is available at: https://www.almirall.com/media/newsroom